Fluvoxamine and long COVID: Post-acute recovery

Rev Med Virol. 2024 Jul;34(4):e2557. doi: 10.1002/rmv.2557.
No abstract available

Publication types

  • Letter

MeSH terms

  • COVID-19 Drug Treatment*
  • COVID-19* / virology
  • Fluvoxamine* / therapeutic use
  • Humans
  • Post-Acute COVID-19 Syndrome
  • SARS-CoV-2* / drug effects
  • Selective Serotonin Reuptake Inhibitors / therapeutic use

Substances

  • Fluvoxamine
  • Selective Serotonin Reuptake Inhibitors